Abbott to Carve Out Nutrition Business Into Independent Company
Abbott plans to spin off its nutrition business into a separate publicly traded company while cutting its 2026 sales growth outlook.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Abbott Laboratories announced its intention to separate its global nutrition business into an independent, publicly traded company following baby formula lawsuits, shortages, and a formula crisis. The coverage concluded with the planned spinoff of the embattled business, leaving the final outcome of the new independent company unstated.
Epilogue added 25d ago, after coverage quieted.
The brief
Recent reporting across major financial publications highlights a significant corporate restructuring decision by Abbott. According to coverage from Investor's Business Daily, Yahoo Finance, Barron's, Bloomberg.com, Reuters, and the Wall Street Journal, Abbott has announced its intention to separate its global nutrition business into an independent, publicly traded company. Alongside this major corporate carve-out, the company also disclosed a reduction to its sales growth view for the year 2026. Financial reporting indicates that this nutrition unit has faced notable operational challenges prior to the planned spinoff, framing the division as an embattled part of the broader corporate structure. The unfolding media coverage heavily emphasizes the immediate financial market reaction and the specific structural nature of the transaction.
Outlets such as Investor's Business Daily and Barron's report that Abbott stock fell following the earnings release and the announcement of the spinoff. The Wall Street Journal and Reuters detail the mechanics of the carve-out, pointing to the nutrition unit as a troubled asset being shed from the parent company's portfolio. Bloomberg.com explicitly identifies the division as an embattled business that is responsible for selling baby formula, tying the segment directly to past controversies and operational friction. Contextual details provided across the coverage frame the decision within a choppy third-quarter earnings performance described by Investor's Business Daily. Abbott is executing this separation against a backdrop of lowered expectations for annual performance, specifically reflected in the downward revision of its 2026 sales growth view reported by Reuters.
The impending spinoff represents a major strategic shift for the organization, detaching the nutrition and baby formula operations from the rest of the company's core medical and healthcare business lines as it navigates current market volatility and financial headwinds. Looking ahead, ongoing coverage indicates that market observers will be monitoring the mechanics and timeline of the independent public company formation. While the headlines establish the intent to separate the nutrition business and cut the 2026 sales outlook, coverage does not yet specify the exact date for the completion of the spinoff or the leadership team designated to run the new entity. Stakeholders and investors will continue tracking regulatory filings, stock performance, and further announcements from Abbott regarding the execution of the carve-out strategy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 27d ago.
Quick answers
What is Abbott planning to do with its nutrition business?
Abbott plans to separate its global nutrition business into an independent, publicly traded company.
How did financial markets react to the announcements?
Abbott stock fell after earnings and the announcement of the spinoff, as reported by Barron's and Investor's Business Daily.
Did Abbott change any financial forecasts?
Yes, Reuters and other outlets report that Abbott cut its 2026 sales growth view.
Coverage (9)
- Abbott Laboratories to spin off nutrition unit at centre of baby formula lawsuits Financial Times · 27d ago
- Abbott Spinning Off Nutrition Business After Formula Crisis, Shortages WSJ · 27d ago
- Opinion: Abbott’s family tree is growing. Will its newest branch thrive like AbbVie? Crain's Chicago Business · 27d ago
- Abbott Yo-Yoes On 'Choppy' Third Quarter As A Key Spinoff Looms Investor's Business Daily · 27d ago
- Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company Yahoo Finance · 27d ago
- Abbott Stock Falls After Earnings. It’s Shedding Its Troubled Nutrition Unit. Barron's · 27d ago
- Abbott Spins Off Embattled Business That Sells Baby Formula Bloomberg.com · 27d ago
- Abbott cuts 2026 sales growth view, plans to spin off nutrition business Reuters · 27d ago
- Abbott to Carve Out Nutrition Business Into Independent Company WSJ · 27d ago
Topics
Related trends
Nike hosts first investor day in 9 years as it tries to rightsize its business
Nike holds its first investor day since 2017, unveiling a 2031 financial framework and Full Stride Ahead strategy to reverse declining sales.
Disney beats fourth-quarter estimates, targets $3 billion in savings through cost-cutting efforts
Disney beat Q4 earnings estimates with $1.77 adjusted EPS on $25.9B revenue and announced a $3B cost-savings target by 2029 alongside a 33% dividend increase.
Diamondback nears $5 billion deal to buy drilling portfolio from Double Eagle, FT says
Diamondback Energy agreed to buy Double Eagle subsidiaries for about 15.56 million shares and $2.15 billion cash, valuing the deal at roughly $5 billion, with closing expected December 21, 2026.
As diabetes spikes in Kashmir, the health lens turns to the fabled wazwan
Diabetes awareness coverage converges on Kashmir, where rising disease rates are prompting scrutiny of the region's traditional wazwan cuisine.
Nvidia bought itself a little breathing room in the Jensen Huang comeback fight
Nvidia secures vital breathing room amid the ongoing Jensen Huang comeback battle according to Business Insider.
Morning Bid: Jensen Huang's last hurrah, and a nervy future for Nvidia
An Indian Nvidia employee publicly praises Jensen Huang for past support during a difficult time.